Skip to content
2000
Volume 11, Issue 1
  • ISSN: 2950-4910
  • E-ISSN: 2950-4902

Abstract

Introduction

A combination of serdexmethylphenidate and dexmethylphenidate are used to treat attention deficiency hyperactivity disorder. A stability-indicating RP-HPLC method has been developed and reported in the literature. As there is no study on the degradation product identification, in this work, the degradation behavior of serdexmethylphenidate and dexmethylphenidate was explored by subjecting combined dosage to the forced degradation study by applying the developed RP-HPLC method. Further, plausible structures and fragmentation patterns of all the degradation products were identified by the LC-MS/MS study.

Methods

The forced degradation study was conducted by exposing the combined dosage form (Azstarys) as per International Council of Harmonization (ICH) guideline Q1A (R2). Using LC-MS/MS, MS spectra were obtained. Based on the m/z values and molecular formula, probable structures of degradation products were elucidated.

Results and Discussion

A total of 7 degradation products were detected, of which, 4 degradation products were formed from serdexmethylphenidate. The remaining 3 degradation products were formed from dexmethylphenidate. The possible structures and fragmentation patterns of all the degradation products were examined with the help of the LC-MS/MS study.

Conclusion

As possible structures and fragmentation patterns were identified by the LC-MS/MS study, this method may help in the development of quality dosage forms, maintaining proper storage conditions, and also in impurity profiling studies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/csch/10.2174/0129504910350918250225110204
2025-02-27
2025-10-22

  • From This Site

    /content/journals/csch/10.2174/0129504910350918250225110204
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FengL. HarukaM. RaulR.S. Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.Neuropsychiatr. Dis. Treat.2006246747310.2147/nedt.2006.2.4.467 19412495
     [Google Scholar]
  2. AvinashD.S. GurvindeK. Drug therapy of attention deficit hyperactivity disorder: Current trends.Mens Sana Monogr.201210456910.4103/0973‑1229.87261 22654382
     [Google Scholar]
  3. KeatingG.M. FiggittD.P. Dexmethylphenidate.Drugs2002621318991904 1221506310.2165/00003495‑200262130‑00009
     [Google Scholar]
  4. HealD.J. GosdenJ. SmithS.L. New drugs to treat ADHD: Opportunities and challenges in research and development.Curr. Top. Behav. Neurosci.2022577912610.1007/7854_2022_332 35507283
     [Google Scholar]
  5. RawatS. KumarV. Impurity profiling: Overview on impurity profiling and reporting methodologies adopted by united states and europE.World J. Pharm. Res.201761420622110.20959/wjpr201714‑9863
     [Google Scholar]
  6. TejasreeT. Raja ShekharN. KrishnaveniN. Unveiling the significance of impurity profiling: A comprehensive exploration of novel analytical techniques for ensuring quality and safety in herbal formulations.Eur. J. Med. Chem. Rep.20241110016610.1016/j.ejmcr.2024.100166
     [Google Scholar]
  7. TeasdaleA. ElderD. NimsR.W. International Conference on HarmonizationGeneva, Switzerland2009
     [Google Scholar]
  8. RamachandraB. Development of impurity profiling methods using modern analytical techniques.Crit. Rev. Anal. Chem.20174712436 2707083010.1080/10408347.2016.1169913
     [Google Scholar]
  9. BatistaJ.M.M. GuimarãesL.A.F. SoaresJ.E.S. FontelesM.M.F. CarvalhoT.M.J.P. Determination of Enantiomeric Methylphenidate in Human Plasma by High Performance Liquid Chromatography.Int. J. Pharm. Tech. Res.201710211411910.20902/IJPTR.2017.10117
     [Google Scholar]
  10. Xue-MeiL. LiD. XinG. Li-YuanJ. MicroRNA mediated regulation in lung adenocarcinoma: Signaling pathways and potential therapeutic implications.Acta Pharm. Sin. B201449838810.3892/or.2023.8648
     [Google Scholar]
  11. SeçilirA. SchrierL. BijleveldY.A. ToerscheJ.H. JorjaniS. BurggraafJ. van GervenJ. MathôtR.A.A. Determination of methylphenidate in plasma and saliva by liquid chromatography/tandem mass spectrometry.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2013923-924222810.1016/j.jchromb.2013.01.027 23454305
     [Google Scholar]
  12. ChennamaneniN.K. NagappanK. A stability indicating method development and validation for determination of Methylphenidate Hydrochloride and its impurities in solid pharmaceutical oral dosage form by RP-HPLC as per ICH guidelines.J. Chem. Pharm. Res.20157606629
     [Google Scholar]
  13. SharonM.P. Determination of methylphenidate and its metabolite ritalinic acid in urine by liquid chromatography/tandem mass spectrometry.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2012881202610.1016/j.jchromb.2011.11.007 22204874
     [Google Scholar]
  14. PoojaB. AndrewK. WilliamF. Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system.J. Pharm. Anal.2018834935610.1016/j.jpha.2017.12.002 30595940
     [Google Scholar]
  15. AllenS.A. PondB.B. Chromatographic and electrophoretic strategies for the chiral separation and quantification of d‐ and l‐ threo methylphenidate in biological matrices.Biomed. Chromatogr.201428111554156410.1002/bmc.3312 25196779
     [Google Scholar]
  16. ZhuH.J. PatrickK.S. MarkowitzJ.S. Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: Application to human ethanol interactions.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.201187911-1278378810.1016/j.jchromb.2011.02.033 21402502
     [Google Scholar]
  17. TalariS. AnuradhaV. BoddapatiS.N.M. AyithabotlaK.S.P. Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR.J. Pharm. Res.202133203211
     [Google Scholar]
  18. RayuduS. ManoranjaniM. Sekhara ReddyD.R. Analytical method development and validation of dexmethylphenidate and serdexmethylphenidate by using RP-HPLC in bulk and pharmaceutical dosage form.Int. J. Appl. Pharma.20221411011510.22159/ijap.2022v14i2.43515
     [Google Scholar]
  19. VeenaB. AjithaM. A validated stability indicating Rp-Hplc method development and validation for simultaneous estimation of serdexmethylphenidate and dexmethylphenidate in pharmaceutical dosage form.World J. Pharm. Sci.202210303710.54037/WJPS.2022.101004
     [Google Scholar]
  20. TejaswiM. PrathibhadanC. SudhakarM. A new stability indicating RP-HPLC method development andvalidation for the simultaneous estimation of serdexmethylphenidate and dexmethylphenidate in pharmaceuticaldosage form.IJPPR202226122133
     [Google Scholar]
  21. GolluG. GummadiS. A novel stability indicating RP-HPLC method for simultaneous quantification of serdexmethylphenidate and dexmethylphenidate in fixed dosage form.J. Chromatogr. Sci.202361435836510.1093/chromsci/bmac011 35152281
     [Google Scholar]
  22. Pridhvi KrishnaG. SundararajanR. Development and validation of stability indicating uplc method for the simultaneous estimation of serdexmethylphenidate and dexmethylphenidate in bulk and their combined dosage form.YMER Digital2022215809710.37896/YMER21.05/11
     [Google Scholar]
  23. Vasavi DeviD. Siva JyothiS. SrinithyaS. ShanawazS. Nelson KumarS. PravallikaM. Stability indicating RP-HPLC method development and validation for simultaneous estimation of serdexmethylphenidate and dexmethylphenidate in bulk and formulation.Acta Scient. Pharma. Sci.20226606710.31080/ASPS.2022.06.0917
     [Google Scholar]
  24. KelaniK.M. NassarA.M.W. OmranG.A. MorshedyS. ElsonbatyA. TalaatW. Chromatographic reversed HPLC and TLC-densitometry methods for simultaneous determination of serdexmethylphenidate and dexmethylphenidate in presence of their degradation products—with computational assessment.BMC Chem.20231717610.1186/s13065‑023‑00986‑3 37454105
     [Google Scholar]
  25. 2003https://database.ich.org/sites/default/files/Q1A
  26. ChristopherL.M. JamesS.R. TiffanyM.J. JohnJ.N. HilkkaI.K. Losses of CO and CO2 upon collision-activated dissociation of substituted 2-methoxyphenoxides after methyl radical loss.Int. J. Mass Spectrom.202045611639710.1016/j.ijms.2020.116397
     [Google Scholar]
  27. TalluriM.V.N.K. KeshariK.K. KalariyaP.D. SrinivasR. Selective separation and characterization of the stress degradation products of ondansetron hydrochloride by liquid chromatography with quadrupole time‐of‐flight mass spectrometry.J. Sep. Sci.201538101625163210.1002/jssc.201401305 25727389
     [Google Scholar]
  28. EveraldoF.K. LauraB. BenjaminA. WolfgangB. NorbertH. HelmutB. UlrikeH. CarstenB. TorstenB. Mechanochemical oxidative degradation of thienopyridine containing drugs: Toward a simple tool for the prediction of drug stability.ACS Cent. Sci.20239115011510.1021/acscentsci.3c00167 37396854
     [Google Scholar]
  29. VivekD. SaranjitS. AnkitB. Bhoopendra SinghK. LaximanV. Vijaya MadhyanapuG. GananadhamuS. Stress degradation study on entrectinib and characterization of its degradation products using HRMS and NMR.J. Pharm. Biomed. Anal.202220811445910.1016/j.jpba.2021.114459
     [Google Scholar]
  30. Tyler DavidsonJ. PiacentinoE.L. SasieneZ.J. AbiedallaY. DeRuiterJ. ClarkC.R. BerdenG. OomensJ. RyzhovV. JacksonG.P. Identification of novel fragmentation pathways and fragment ion structures in the tandem mass spectra of protonated synthetic cathinones.Forensic Chem.20201910024510.1016/j.forc.2020.100245
     [Google Scholar]
  31. JiangC. HanH. DaiJ. WangZ. ChaiY. WangC. LiuX. LuC. ChenH. Insights into stress degradation behavior of gibberellic acid by UHPLC Q-Exactive Orbitrap mass spectrometry.Food Chem.2022367130662 3434379910.1016/j.foodchem.2021.130662
     [Google Scholar]
  32. DhimanV. PatilK. VelipL. TalluriM.V.N.K. GananadhamuS. Comprehensive degradation profiling and influence of different oxidizing reagents on tinoridine hydrochloride: Structural characterization of its degradation products using HPLC and HRMS.Rapid Commun. Mass Spectrom.2022361e921010.1002/rcm.9210 34619000
     [Google Scholar]
  33. GolluG. GummadiS. Forced degradation study of zanubrutinib: An LC-PDA and LC-MS approach.J. Chromatogr. Sci.20228080781610.1093/chromsci/bmab137
     [Google Scholar]
/content/journals/csch/10.2174/0129504910350918250225110204
Loading
A LC-MS/MS Approach for the Identification of Degradation Products of Serdexmethylphenidate and Dexmethylphenidate and Elucidation of their Degradation Pathway
Curr Spectrosc Chromatogr 11, E29504910350918 (2025); https://doi.org/10.2174/0129504910350918250225110204
/content/journals/csch/10.2174/0129504910350918250225110204
/content/journals/csch/10.2174/0129504910350918250225110204
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): attention deficiency hyperactivity disorder; degradation products; dexmethylphenidate; LC-MS/MS; RP-HPLC method; Serdexmethylphenidate
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test